Professor Michael Barry:

I would say that with regard to, for example, fenfluramine, which is for Dravet syndrome, as the Deputy will know, we did that HTA in 54 days, so it can be done quickly and we would strive to do that.

On denosumab, I do not know the answer to that. I am sure it is probably because of the application that was put in to the HSE but we can check that out for the Deputy.